Innovating Drug Discovery

Pioneering Solutions for a Healthier Tomorrow

Leading the Way in Drug Innovation
Shaping the Future of Medicine, One Discovery at a Time

Services

Target Identification

Utilizing advanced technologies to identify molecular targets that are crucial in disease pathology, ensuring early and precise intervention.

Compound Screening

High-throughput screening of chemical compounds to rapidly identify potential drug candidates with therapeutic benefits.

Preclinical Testing

Robust preclinical testing protocols to evaluate drug efficacy and safety, paving the way for successful clinical trials.

About Us
The foundation Stichting Eigen Regie,kvk 70567573 was established on januari 8 th 2018.                               It's core activities were wound management.This came to a hold in 2020 during Covid-19.It's expertise led to the development of new antibiotics.                       Beneluxbio does its own in-house research and has licensed compounds from Liberpharma.                         Liberpharma became in 2022 the trading name of the Stichting Eigen Regie.
With a commitment to innovation and patient care, we aim to develop new medicines that address infectious diseases and  Multiple myeloma.
Many compounds were designed and developed under a program of the NCI
Director is mr. J.H.A.Cornelesen
We are gratefull to our former director mr. R.G.Dassen ( Itteren,Netherlands)for his relentless commitment to the Stichting Eigen Regie

Collaborations,Pipeline,Patents

 Collaborative Arrangements Beneluxbio is in negotiation to enter into collaborative arrangements with Dutch SME's(Mkb ),Flemish Kmo's, Institutions and Universities to close collaboration agreements 

 30 investigational new molecular entities are registered at iDEPOT for chemical synthesis and testing in bioassays We have a location in Flanders that supports our operations in the Flemish region ( VLAIO) 

 Beneluxbio is diversifying its portfolio and executing on its strategy which is broadly based on two strategic pillars: antibiotics and rare diseases (immuno-oncology).One exception is the development of a non-opioid,small molecule analgesic that works as a selective Ion channel modulator 

 European Innovation programme South Netherlands 

 With support from the European Union Medegefinancierd door de Europese Unie 

 With support from the province Limburg Medegefinancierd door de provincie Limburg 

Contact

  • Manhattan, New York, NY, United States

Contact

  • Manhattan, New York, NY, United States